Procore Technologies (NYSE:PCOR) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker9Good afternoon. Thank you for attending today's Procore Technologies, Inc., FY 25 Q4 earnings call. My name is Tamia, and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call, with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I would now like to pass the conference ov ...

Financial Data and Key Metrics Changes - Twilio reported record revenue of $1.4 billion in Q4 2025, representing a 14% year-over-year increase on a reported basis and 12% on an organic basis [4][13] - For the full year, revenue reached $5.1 billion, reflecting a 14% reported growth and 13% organic growth [13] - Non-GAAP income from operations for Q4 was $256 million, up 30% year-over-year, while for the full year, it was $924 million, a 29% increase [17][18] - Free cash flow for Q4 was also $256 million, and for the full year, it increased by 44% year-over-year to $945 million [14][19] - The company achieved its first full year of GAAP profitability with a GAAP income from operations of $158 million [14] Business Line Data and Key Metrics Changes - Voice revenue growth accelerated to the high teens in Q4, driven by strong adoption of voice AI, which saw over 60% year-over-year growth [15][14] - Messaging revenue growth was solid, particularly during Cyber Week, contributing to overall strong performance [15] - Software add-on revenue grew over 20% year-over-year, with Verify growing more than 25% for two consecutive quarters [16] - The number of large deals closed (over $500,000) increased by 36% year-over-year, indicating strong demand across business lines [6] Market Data and Key Metrics Changes - Twilio's dollar-based net expansion rate was 109% in Q4, reflecting improving growth trends [16] - The company saw a 34.5% year-over-year increase in messages sent during Cyber Week, with 6.99 billion messages sent [9] - RCS volume grew roughly 5x quarter-over-quarter, indicating strong traction in this area [10] Company Strategy and Development Direction - Twilio aims to be a foundational infrastructure layer in the age of AI, moving beyond just providing communication channels [5] - The company is focused on delivering essential infrastructure powered by contextual data and evolving automation, such as Voice AI, to help customers build personalized relationships [6][12] - A strategic partnership with AEG was established to enhance real-time, personalized communications at live events [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum into 2026, supported by a robust innovation roadmap and strong execution [12][24] - The company anticipates reported revenue growth of 11.5%-12.5% and organic growth of 8%-9% for the full year 2026 [21] - Management acknowledged the impact of increased A2P fees on margins but emphasized that these fees do not affect the ability to generate profit dollars [22][40] Other Important Information - Twilio completed $198 million in share repurchases in Q4 and $855 million for the full year, representing 90% of 2025 free cash flow [19][20] - The company is focused on cost discipline, with a net burn rate of just 1.5% in 2025, well below the target [19] Q&A Session Summary Question: What drove the voice strength in Q4? - Management noted broad adoption across customer cohorts, with strong performance in self-service and ISV channels, as well as direct enterprise use cases [27][28] Question: Can you provide visibility on Q1 guidance? - Management expressed confidence in Q1 guidance, citing broad-based strength in voice and messaging, with both channels growing in the high teens [31] Question: What is driving the growth in messaging? - Management indicated broad-based strength across multiple products, with no specific driver identified, but overall positive trends in messaging [42] Question: How is Twilio positioned against competitors? - Management highlighted differentiated technology and a strong developer experience as key advantages, allowing Twilio to capture market share [52][55] Question: What is the outlook for Voice AI growth? - Management sees strong growth potential in both enterprise and voice AI companies, with enterprise expected to drive long-term growth [59][60]

Federal Realty Investment Trust (NYSE:FRT) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker13Good day, and welcome to the Federal Realty Investment Trust fourth quarter 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypa ...

Summary of Amgen Conference Call - February 12, 2026 Company Overview - **Company**: Amgen (NasdaqGS:AMGN) - **Focus**: Development of innovative therapies for autoimmune diseases and other conditions Key Products and Developments UPLIZNA - **Indications**: Plans to initiate Phase III studies for autoimmune hepatitis (AIH) and chronic inflammatory demyelinating polyneuropathy (CIDP) later in 2026 - **Mechanism**: B-cell depleter targeting CD19, effective in conditions driven by pathogenic B-cells - **Market Potential**: - CIDP prevalent pool in the U.S. estimated at 35,000 patients, with 7,000-10,000 new cases annually - AIH likely has a larger patient population, though exact numbers are difficult to ascertain - **Rationale**: Proven effectiveness in similar conditions like IgG4-related disease and generalized myasthenia gravis supports the potential for UPLIZNA in AIH and CIDP [1][2][3][4][6] Daxdilimab - **Indications**: Positive Phase II results in discoid lupus; previously failed in systemic lupus erythematosus (SLE) - **Mechanism**: Targets immunoglobulin-like transcript seven protein (ILT-7), depleting plasmacytoid dendritic cells involved in interferon production - **Clinical Results**: - Discoid lupus study met primary endpoint of reduced disease severity at week 24 - Secondary endpoint also showed clinical benefit - **Future Plans**: Considering Phase III study for discoid lupus, with potential for broader indications in autoimmune diseases driven by plasmacytoid dendritic cells [9][10][11][13][16] Dazodalibep - **Indications**: Targeting Sjögren's syndrome with two ongoing Phase III studies - **Mechanism**: Inhibits CD40 ligand, disrupting B-cell activation and downstream inflammatory cascades - **Clinical Management**: Current management is symptomatic; no definitive treatments exist - **Phase II Results**: Showed improvement in disease activity index and patient-reported outcomes, providing confidence for Phase III studies [18][26][29][32] TEZSPIRE - **Indications**: Recently expanded label for chronic rhinosinusitis with nasal polyps - **Mechanism**: Targets TSLP, addressing upstream drivers of inflammation, differentiating it from therapies targeting downstream cytokines (IL-4, IL-5, IL-13) - **Clinical Results**: Phase 3 Waypoint study showed significant reduction in nasal polyp severity and decreased need for surgery - **Market Potential**: High overlap between chronic rhinosinusitis and asthma (approximately 20% of asthma patients also have nasal polyps), enhancing TEZSPIRE's market reach [35][36][37][42][45] Eosinophilic Esophagitis (EoE) - **Unmet Need**: Current treatments are limited, primarily involving proton pump inhibitors and corticosteroids - **Prevalence**: Estimated at 1 in 700 people in the U.S. - **Phase III Study**: Expected data in the second half of 2026, with potential for TEZSPIRE to address this unmet need [47][49][51] Competitive Landscape - **Dazodalibep vs. Nipocalimab**: Dazodalibep is the first therapy to demonstrate efficacy in both subgroups of Sjögren's syndrome in Phase II, with ongoing Phase III studies to confirm its effectiveness [32][34] Future Outlook - **Execution Focus**: Amgen aims to build penetration in existing indications before exploring new ones for TSLP-targeted therapies - **Inhaled TSLP Therapy**: AMG 104, an inhaled TSLP antibody fragment, is in Phase II trials, with potential to provide an alternative to injected biologics for asthma management [65][66][70][74] Conclusion - Amgen is positioned to leverage its innovative therapies across multiple autoimmune conditions, with significant clinical data supporting the efficacy of its products. The company is focused on executing its current strategies while preparing for future opportunities in the evolving therapeutic landscape.

Toast (NYSE:TOST) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker8Good afternoon. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to Toast's fourth quarter and full year 2025 earnings conference call. Today's call will be 45 minutes. I'll now turn the call over to Michael Senno, Senior Vice President of Finance. You may begin your conference.Speaker7Thank you, operator. Welcome to Toast's earnings conference call for the fourth qua ...

Yelp (NYSE:YELP) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker7Thank you for standing by. At this time, I would like to welcome everyone to today's Q4 2025 Yelp Incorporated Earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star, followed by the number one on your telephone keypad. Once again, star one. If you'd lik ...

Bannerman Energy (OTCPK:BNNL.F) Update / briefing February 12, 2026 04:45 PM ET Company ParticipantsAndrew Hines - Head of ResearchBrandon Munro - Executive ChairmanGlyn Lawcock - Founding Partner and Head of Resources ResearchMilan Tomic - Metals and Mining AssociateOperatorThank you. I'd now like to welcome Brandon Munro, Executive Chairman, to begin the conference. Brandon, over to you.Brandon MunroThanks very much everyone for joining us. It's really a transformational and very exciting moment in the co ...

Arteris (NasdaqGM:AIP) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsCharlie Janac - CEOErica Mannion - Investor RelationsNick Hawkins - CFOConference Call ParticipantsGus Richard - AnalystKevin Garrigan - Senior Equity Research AnalystMadison DePaula - AnalystOperatorGood afternoon, everyone, and welcome to the Arteris fourth quarter and full year 2025 earnings call. Please note this call is being recorded and simultaneously webcast. All material contained in the webcast is sole p ...

Flux Power (NasdaqCM:FLUX) Q2 2026 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsJoel Achramowicz - Managing DirectorKevin Royal - CFOKrishna Vanka - CEOConference Call ParticipantsCraig Irwin - Managing Director and Senior Research AnalystRob Brown - Senior Research Analyst, Founding Partner, and Chief Strategy OfficerSameer Joshi - Senior Equity Research AnalystOperatorGood afternoon, and welcome to Flux Power's fiscal second quarter 2026 earnings conference call. At this time, all parti ...

Pinterest (NYSE:PINS) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAndrew Somberg - VP of Investor Relations and TreasurerBill Ready - CEOBrian Nowak - Managing DirectorEric Sheridan - Managing DirectorJulia Donnelly - CFORon Josey - Managing DirectorConference Call ParticipantsColin Sebastian - Baird logo Managing Director and Senior Research Analyst for Internet and Digital MediaDoug Anmuth - Managing Director and Internet AnalystJustin Patterson - Managing Director and Equity R ...